-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 NndqKZwcXUPsvknrn0CzxABVBM/JNWij4D+NQBgw8+0nMiVqg9NeFQ4piQGXQq+M
 XZxSKyqR3Bv7CkyAym1B2A==

<SEC-DOCUMENT>0000842023-09-000011.txt : 20090428
<SEC-HEADER>0000842023-09-000011.hdr.sgml : 20090428
<ACCEPTANCE-DATETIME>20090428093831
ACCESSION NUMBER:		0000842023-09-000011
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090428
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090428
DATE AS OF CHANGE:		20090428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TECHNE CORP /MN/
		CENTRAL INDEX KEY:			0000842023
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				411427402
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17272
		FILM NUMBER:		09774258

	BUSINESS ADDRESS:	
		STREET 1:		614 MCKINLEY PL N E
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
		BUSINESS PHONE:		6123798854

	MAIL ADDRESS:	
		STREET 1:		614 MCKINLEY PLACE NE
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>k8q.txt
<DESCRIPTION>8-K
<TEXT>
                      SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                FORM 8-K

                              CURRENT REPORT

                  PURSUANT TO SECTION 13 OR 15(d) OF THE
                     SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): April 28, 2009

                            TECHNE CORPORATION
             (Exact Name of Registrant as Specified in Charter)


       Minnesota                     0-17272             41-1427402
(State or Other Jurisdiction       (Commission         I.R.S. Employer
of Incorporation)                  File Number)      Identification No.)

                614 Mckinley Place NE
                   Minneapolis, MN                       55413
       (Address of Principal Executive Offices)       (Zip Code)

     Registrant's telephone number, including area code:  (612) 379-8854

                              Not Applicable
      (Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:

/ /   Written communications pursuant to Rule 425 under the Securities Act
      17 CFR 230.425)

/ /   Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

/ /   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

/ /   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))


<PAGE>



Item 2.02  Results of Operations and Financial Condition

A copy of the press release issued by Techne Corporation on April 28,
2009, describing the results of operations for the quarter and nine months
ended March 31, 2009 and its financial condition as of March 31, 2009,
is attached hereto as Exhibit 99.1.

Segment information for Techne Corporation for the quarter and nine months
ended March 31, 2009 which has been included on Techne Corporation's
website (www.techne-corp.com), is attached hereto as Exhibit 99.2.

The information in this Form 8-K and the Exhibits attached hereto shall not
be deemed "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933 or the Exchange Act, except as
expressly set forth by specific reference in such filing.


Item 9.01 Financial Statements and Exhibits

     (d) Exhibits

         99.1 Press Release dated April 28, 2009.

         99.2 Segment information for the quarter and nine months ended
              March 31, 2009.






                            SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Dated: April 28, 2009                 TECHNE CORPORATION
                                      By: /s/ Thomas E. Oland
                                      ---------------------------
                                      Name: Thomas E. Oland
                                      Title: President and Chief
                                        Executive Officer



                          EXHIBIT INDEX

    Exhibit No. Description
    ----------- -----------
       99.1     Press release of Techne Corporation dated April 28, 2009.

       99.2     Segment information for Techne Corporation for the quarter
                and nine months ended March 31, 2009.

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>q309pressrelease.txt
<DESCRIPTION>EARNINGS RELEASE
<TEXT>

           TECHNE CORPORATION RELEASES UNAUDITED THIRD QUARTER
                 RESULTS FOR FISCAL YEAR 2009

Minneapolis/April 28, 2009/-- Techne Corporation's (NASDAQ: TECH)
consolidated net earnings for the quarter ended March 31, 2009 decreased 6.6%
to $27.6 million or $.74 per diluted share compared with $29.6 million or
$.76 per diluted share for the quarter ended March 31, 2008.  For the nine
months ended March 31, 2009, Techne's consolidated net earnings increased
4.7% to $79.9 million or $2.10 per diluted share compared with $76.3 million
or $1.94 per diluted share for the nine months ended March 31, 2008.  Net
earnings as a percentage of net sales was 40.1% for the nine months ended
March 31, 2009 as compared to 40.2% in the first nine months of last year.

Foreign currency fluctuations and general economic conditions continued to
have a negative impact on consolidated net sales and earnings in the quarter
ended March 31, 2009. The change in exchange rates used to convert foreign
currencies (primarily British pound sterling and euros) to U.S. dollars
reduced net earnings by $1.5 million ($.04 per diluted share) for the quarter
and $3.3 million ($.09 per diluted share) for the nine months ended March 31,
2009, as compared to the same periods in last fiscal year.

Consolidated net sales for the quarter and nine months ended March 31, 2009
were $67.9 million and $199.1 million, respectively. This was a 2.4% decrease
and a 5.0% increase from the quarter and nine months ended March 31, 2008,
respectively. Consolidated net sales were negatively affected by the strength
of the U.S. dollar as compared to foreign currencies. Excluding the effect of
changes in foreign currency exchange rates, consolidated net sales increased
2.9% and 8.3% for the quarter and nine months ended March 31, 2009,
respectively, from the comparable prior year periods.

Biotechnology net sales, which include sales by R&D Systems' Biotechnology
Division, R&D Systems China and BiosPacific, were $45.1 million for the
quarter ended March 31, 2009, essentially the same as in the quarter ended
March 31, 2008.  Biotechnology sales were $131.6 million for the nine months
ended March 31, 2009, an increase of 6.9% over the same period last year.
North American biotechnology sales to industrial pharmaceutical and
biotechnology customers declined approximately 5% during the third quarter of
fiscal 2009.  Biotechnology sales to academic and Pacific Rim distributor
customers grew about 3% during the same period.  The Company attributes the
lower third quarter sales growth rate to customer caution in a time of
economic uncertainty.

R&D Europe's net sales for the quarter and nine months ended March 31, 2009
were $18.3 million and $54.5 million, decreases of 9.6% and 0.3%,
respectively, from the same prior-year periods.  R&D Europe's net sales
increased 8.5% and 11.3% for the quarter and nine months ended March 31, 2009
when measured at currency rates in effect in the comparable prior periods.

Hematology net sales for the quarter and nine months ended March 31, 2009
were $4.4 million and $12.9 million, increases of 5.4% and 9.3%,
respectively, compared to the quarter and nine months ended March 31, 2008.

Consolidated gross margins were 78.9% and 79.5% for the quarter and nine
months ended March 31, 2009, respectively, compared to 79.7% and 79.4% for
the quarter and nine months ended March 31, 2008, respectively. The decrease
in gross margins in the third quarter was primarily caused by lower gross
margins in Europe resulting from unfavorable exchange rates.

Selling, general and administrative expenses for the quarter and nine months
ended March 31, 2009 decreased $1.9 million (21.5%) and $2.1 million (7.7%),
respectively from the quarter and nine months ended March 31, 2008. The
decrease in selling, general and administrative expenses from the comparable
prior-year periods were the result of the following (in thousands):

                                                 Quarter  Nine Months
                                                 -------- -----------
Reduction in profit sharing expense              $(1,326)   $(1,943)
Change in exchange rates to convert foreign
  expenses to U.S. dollars                          (651)    (1,538)
Other, including annual wage, salary
  and benefits increases                              44      1,356
                                                 -------    -------
                                                 $(1,933)   $(2,125)
                                                 =======    =======

Research and development expenses decreased $30,000 (0.5%) and increased
$983,000 (5.9%), respectively, for the quarter and nine months ended March
31, 2009 from the comparable prior-year periods.

Interest income decreased $1.6 million and $2.8 million for the quarter and
nine months ended March 31, 2009, respectively, from the comparable prior-
year periods, primarily as a result of lower rates of return on cash and
available-for-sale investments and, to a lesser extent, to lower cash and
available-for-sale investment balances.

The effective tax rate for both the quarter and nine months ended March 31,
2009 was 32.3% as compared to effective tax rates of 31.2% and 32.7%,
respectively, from the same prior-year periods. The effective rate in the
quarter ended March 31, 2008 was positively impacted by changes in state
apportionment estimates. The Company expects its fiscal 2009 effective income
tax rate to range from approximately 32.0% to 33.0%.

In November 2007, the Company's Board of Directors authorized the repurchase
and retirement of up to $150 million of the Company's common stock.  The
Company repurchased approximately 213,000 shares of its common stock during
the third quarter of fiscal 2009 for approximately $10.5 million.
Approximately $7.5 million remains available for the repurchase of shares
under this authorization.


Forward Looking Statements:

This earnings release contains forward-looking statements within the meaning
of the Private Litigation Reform Act. These statements, including the
Company's expectations as to consolidated income tax rates, involve risks and
uncertainties that may affect the actual results of operations. The following
important factors, among others, have affected and, in the future, could
affect the Company's actual results: the introduction and acceptance of new
biotechnology and hematology products, the levels and particular directions
of research by the Company's customers, the impact of the growing number of
producers of biotechnology research products and related price competition,
general economic conditions, the retention of hematology OEM and proficiency
survey business, the impact of currency exchange rate fluctuations, and the
costs and results of research and product development efforts of the Company
and of companies in which the Company has invested or with which it has
formed strategic relationships.

For additional information concerning such factors, see the Company's annual
report on Form 10-K and quarterly reports on Form 10-Q as filed with the
Securities and Exchange Commission.  We undertake no obligation to update or
revise any forward-looking statements we make in this release due to new
information or future events.  Investors are cautioned not to place undue
emphasis on these statements.

                    *  *  *  *  *  *  *  *  *  *  *  *

Techne Corporation has two operating subsidiaries:  Research and Diagnostic
Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe,
Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty
manufacturer of biological products.  R&D Systems has two subsidiaries,
BiosPacific, Inc. (BiosPacific), located in Emeryville, California and R&D
Systems China Co. Ltd., (R&D China), located in Shanghai, China.  BiosPacific
is a worldwide supplier of biologics to manufacturers of in vitro diagnostic
systems and immunodiagnostic kits. R&D China and R&D Europe distribute
biotechnology products.


Contact:  Greg Melsen, Chief Financial Officer
          Kathy Backes, Controller
          (612) 379-8854



                              TECHNE CORPORATION
                    CONSOLIDATED STATEMENTS OF EARNINGS
                    (In thousands, except per share data)
                                      (Unaudited)

                                          QUARTER ENDED   NINE MONTHS ENDED
                                         ---------------  -----------------
                                         3/31/09 3/31/08   3/31/09  3/31/08
                                         ------- -------  -------- --------
Net sales                                $67,866 $69,522  $199,066 $189,651
Cost of sales                             14,316  14,146    40,832   39,001
                                         ------- -------  -------- --------
Gross margin                              53,550  55,376   158,234  150,650
                                         ------- -------  -------- --------
Operating expenses:
 Selling, general and administrative       7,061   8,994    25,604   27,729
 Research and development                  5,809   5,839    17,565   16,582
 Amortization of intangible assets           240     283       720      853
  Total operating expenses                13,110  15,116    43,889   45,164
                                         ------- -------  -------- --------
Operating income                          40,440  40,260   114,345  105,486
                                         ------- -------  -------- --------
Other income (expense):
 Interest income                           1,504   3,155     6,596    9,405
 Other non-operating expense, net         (1,103)   (423)   (3,002)  (1,565)
                                         ------- -------  -------- --------
  Total other income                         401   2,732     3,594    7,840
                                         ------- -------  -------- --------
Earnings before income taxes              40,841  42,992   117,939  113,326
Income taxes                              13,200  13,402    38,083   37,025
                                         ------- -------  -------- --------
Net earnings                             $27,641 $29,590  $ 79,856 $ 76,301
                                         ======= =======  ======== ========
Earnings per share:
 Basic                                   $  0.74 $  0.76  $   2.10 $   1.94
 Diluted                                 $  0.74 $  0.76  $   2.10 $   1.94
Weighted average common
 shares outstanding:
  Basic                                   37,427  39,000    37,986   39,296
  Diluted                                 37,499  39,108    38,085   39,396



                              TECHNE CORPORATION
                          CONSOLIDATED BALANCE SHEETS
                                (In thousands)
                                 (Unaudited)
                                                 3/31/09     6/30/08
                                                --------    --------
ASSETS
Cash and equivalents                            $133,821    $166,992
Short-term available-for-sale investments         33,296      39,353
Trade accounts receivable                         31,593      31,747
Other receivables                                  3,020       1,585
Inventory                                         10,749       9,515
Other current assets                              10,196       9,241
                                                --------    --------
  Current assets                                 222,675     258,433
                                                --------    --------

Available-for-sale investments                    66,925      87,384
Property and equipment, net                       97,428     101,722
Goodwill and intangible assets, net               28,312      29,032
Other non-current assets                          26,463      30,798
                                                --------    --------
  Total assets                                  $441,803    $507,369
                                                ========    ========
LIABILITIES
Current liabilities                             $ 14,914    $ 20,239
Stockholders' equity                             426,889     487,130
                                                --------    --------
  Total liabilities and equity                  $441,803    $507,369
                                                ========    ========

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>seg309.txt
<DESCRIPTION>SEGMENT RESULTS
<TEXT>
                                     SEGMENT INFORMATION

                           TECHNE CORPORATION AND SUBISIDARIES
                         (in thousands of $'s, except per share data)
<TABLE>
<CAPTION>
                                                        Increase (Decrease)
                             Fiscal 2009                  From Fiscal 2008
               ------------------------------------- ----------------------------
                First Second  Third         Percent   First Second   Third
                 Qtr    Qtr    Qtr     YTD  Of Sales   Qtr    Qtr     Qtr    YTD
               ------ ------ ------ ------- -------- ------ ------  ------  -----
<S>           <C>    <C>    <C>    <C>      <C>     <C>    <C>     <C>     <C>
Sales          69,324 61,876 67,866 199,066   100%   11,337   (266) (1,656) 9,415
Cost of sales  13,086 13,430 14,316  40,832    21%      982    679     170  1,831
               ------ ------ ------ ------- -------- ------ ------  ------  -----
Gross margin   56,238 48,446 53,550 158,234    79%   10,355   (945) (1,826) 7,584

Gross margin
 percentage     81.1%  78.3%  78.9%   79.5%

SG&A expense    8,840  9,703  7,061  25,604    13%      750   (942) (1,933)(2,125)
R&D expense     5,910  5,846  5,809  17,565     9%      729    284     (30)   983
Amortization
 expense          240    240    240     720     -       (48)   (42)    (43)  (133)
Interest
 income        (2,887)(2,205)(1,504) (6,596)   (3%)     111  1,047   1,651  2,809
Other non-
 operating
 ex., net       1,187    712  1,103   3,002     1%      618    139     680  1,437
               ------ ------ ------ ------- -------- ------ ------  ------  -----
               13,290 14,296 12,709  40,295    20%    2,160    486     325  2,971
               ------ ------ ------ ------- -------- ------ ------  ------  -----
Earnings before
 income taxes  42,948 34,150 40,841 117,939    59%    8,195 (1,431) (2,151) 4,613
Income taxes   14,355 10,528 13,200  38,083    19%    2,674 (1,414)   (202) 1,058
               ------ ------ ------ ------- -------- ------ ------  ------  -----
               28,593 23,622 27,641  79,856    40%    5,521    (17) (1,949) 3,555
               ====== ====== ====== ======= ======== ====== ======  ======  =====

Diluted
 earnings per
 share            .74    .62    .74    2.10
Weighted avg.
 diluted shares
 outstanding   38,747 37,992 37,499  38,085

</TABLE>


                                  BIOTECHNOLOGY (1)
                                 (in thousands of $'s)
<TABLE>
<CAPTION>
                                                        Increase (Decrease)
                             Fiscal 2009                  From Fiscal 2008
               ------------------------------------- ----------------------------
                First Second  Third         Percent   First Second   Third
                 Qtr    Qtr    Qtr    YTD   Of Sales   Qtr    Qtr     Qtr    YTD
               ------ ------ ------ ------- -------- ------ ------  ------ ------
<S>           <C>    <C>    <C>    <C>      <C>     <C>    <C>     <C>    <C>
Sales          53,899 48,643 53,718 156,260    100%   8,571  2,067    806  11,444
Intersegment
 sales         (7,762)(8,311)(8,579)(24,652)         (1,315)  (878)  (757) (2,950)
               ------ ------ ------ -------          ------ ------  ------ ------
               46,137 40,332 45,139 131,608           7,256  1,189      49  8,494

Cost of sales  10,247 11,090 11,080  32,417     21%   1,250  1,478     371  3,099
Intersegment
 sales         (7,461)(8,339)(8,494)(24,294)         (1,287)  (909)   (739)(2,935)
               ------ ------ ------ ------- -------- ------ ------  ------ ------
                2,786  2,751  2,586   8,123             (37)   569    (368)   164

Gross margin   43,351 37,581 42,553 123,485     79%   7,293    620     417  8,330

Gross margin
 percentage     81.0%  77.2%  79.4%   79.3%

SG&A expense    5,141 5,418   4,262  14,821      9%     517   (116)   (995)  (594)
R&D expense     5,717 5,643   5,622  16,982     11%     715    275     (18)   972
Amortization
 expense          240   240     240     720      --     (48)   (42)    (43)  (133)
Interest, net  (1,084) (970)   (853) (2,907)    (1%)    173    339     432    944
Exchange
 loss/(gain)       (2)    1       1      --      --     (36)   (11)      6    (41)
               ------ ------ ------ ------- -------- ------ ------  ------ ------
               10,012 10,332  9,272  29,616     19%   1,321    445    (618) 1,148
               ------ ------ ------ ------- -------- ------ ------  ------ ------
Pretax result  33,339 27,249 33,281  93,869     60%   5,972    175   1,035  7,182
               ====== ====== ====== ======= ======== ====== ======  ====== ======
</TABLE>

(1)	Includes R&D Systems' Biotechnology Division,
BiosPacific, Inc. and R&D China


                               R&D SYSTEMS EUROPE
                         (in thousands of British pounds)
<TABLE>
<CAPTION>
                                                        Increase (Decrease)
                             Fiscal 2009                  From Fiscal 2008
               ------------------------------------- ----------------------------
                First Second  Third         Percent   First Second   Third
                 Qtr    Qtr    Qtr    YTD   Of Sales   Qtr    Qtr     Qtr    YTD
               ------ ------ ------ ------- -------- ------ ------  ------ ------
<S>           <C>    <C>    <C>    <C>      <C>     <C>    <C>     <C>    <C>
Sales          10,175 11,197 12,716  34,088    100%   2,570  1,896   2,536  7,002
Cost of sales   4,260  5,361  6,540  16,161     47%     805  1,308   2,148  4,261
               ------ ------ ------ ------- -------- ------ ------  ------ ------
Gross margin    5,915  5,836  6,176  17,927     53%   1,765    588     388  2,741

Gross margin
 percentage     58.1%  52.1%  48.6%   52.6%

SG&A expense    1,224  1,364  1,191   3,779     11%     110     88      28    226
Interest income  (790)  (583)  (235) (1,608)    (4%)   (107)   190     527    610
Exchange
 loss/(gain)      260    (35)   163     388      1%     356     46     393    795
               ------ ------ ------ ------- -------- ------ ------  ------ ------
                  694    746  1,119   2,559      8%     359    324     948  1,631
               ------ ------ ------ ------- -------- ------ ------  ------ ------
Pretax result   5,221  5,090  5,057  15,368     45%   1,406    264    (560) 1,110
               ====== ====== ====== ======= ======== ====== ====== ======= ======

</TABLE>

                            R&D SYSTEMS EUROPE
                           (in thousands of $'s)

<TABLE>
<CAPTION>
                                                        Increase (Decrease)
                             Fiscal 2009                  From Fiscal 2008
               ------------------------------------- ----------------------------
                First Second  Third         Percent   First Second   Third
                 Qtr    Qtr    Qtr    YTD   Of Sales   Qtr    Qtr     Qtr    YTD
               ------ ------ ------ ------- -------- ------ ------  ------ ------
<S>           <C>    <C>    <C>    <C>      <C>     <C>    <C>     <C>    <C>
Sales          18,941 17,284 18,293  54,518    100%   3,492 (1,743) (1,933)  (184)
Cost of sales   7,931  8,274  9,405  25,610     47%     911    (19)    679  1,571
               ------ ------ ------ ------- -------- ------ ------  ------ ------
Gross margin   11,010  9,010  8,888  28,908     53%   2,581 (1,724) (2,612)(1,755)

Gross margin
 percentage     58.1%  52.1%  48.6%   53.0%

SG&A expense    2,283  2,094  1,714   6,091     11%      21   (505)   (597)(1,081)
Interest income(1,471)  (906)  (338) (2,715)    (5%)    (84)   670   1,176  1,762
Exchange loss     476      5    238     719      1%     674    170     695  1,539
               ------ ------ ------ ------- -------- ------ ------  ------ ------
                1,288  1,193  1,614   4,095      7%     611    335   1,274  2,220
               ------ ------ ------ ------- -------- ------ ------  ------ ------
Pretax result   9,722  7,817  7,274  24,813     46%   1,970 (2,059) (3,886)(3,975)
               ====== ====== ====== ======= ======== ====== ======  ====== ======

</TABLE>


                                    HEMATOLOGY
                               (in thousands of $'s)
<TABLE>
<CAPTION>
                                                        Increase (Decrease)
                             Fiscal 2009                  From Fiscal 2008
               ------------------------------------- ----------------------------
                First Second  Third         Percent   First Second   Third
                 Qtr    Qtr    Qtr    YTD   Of Sales   Qtr    Qtr     Qtr    YTD
               ------ ------ ------ ------- -------- ------ ------  ------ ------
<S>           <C>    <C>    <C>    <C>      <C>     <C>    <C>     <C>    <C>
Sales           4,246  4,260  4,434  12,940    100%     589    288     228  1,105
Cost of sales   2,369  2,405  2,325   7,099     55%     108    129    (141)    96
               ------ ------ ------ ------- -------- ------ ------  ------ ------
Gross margin    1,877  1,855  2,109   5,841     45%     481    159     369  1,009

Gross margin
 percentage     44.2%  43.5%  47.6%   45.1%

SG&A expense      436    398    310   1,144      9%     (31)   (89)   (179)  (299)
R&D expense       193    203    187     583      4%      14      9     (12)    11
Interest, net    (102)   (91)   (80)   (273)    (2%)     18     34      43     95
               ------ ------ ------ ------- -------- ------ ------  ------ ------
                  527    510    417   1,454     11%       1    (46)   (148)  (193)
               ------ ------ ------ ------- -------- ------ ------  ------ ------
Pretax result   1,350  1,345  1,692   4,387     34%     480    205     517  1,202
               ====== ====== ====== ======= ======== ====== ======  ======  =====

</TABLE>



                             CORPORATE AND OTHER (2)
                               (in thousands of $'s)
<TABLE>
<CAPTION>
                                                           Increase (Decrease)
                                Fiscal 2009                  From Fiscal 2008
                 ---------------------------- ----------------------------
                   First Second  Third          First Second   Third
                    Qtr    Qtr    Qtr    YTD     Qtr    Qtr     Qtr    YTD
                  ------ ------ ------ ------- ------ ------  ------ ------
<S>              <C>    <C>    <C>    <C>     <C>    <C>     <C>    <C>

Interest income      230    238    233     701     (4)    (4)     --     (8)
Rental income         99    131    115     345     32     20      24     76
                  ------ ------ ------ ------- ------ ------  ------ ------
                     329    369    348   1,046     28     16      24     68

SG&A expense         980  1,793    775   3,548    243   (232)   (162)  (151)
Other-Building
 expenses            553    551    573   1,677      9    (49)    (60)  (100)
Other-Equity
 Investment losses   259    286    406     951      3     49      63    115
                  ------ ------ ------ ------- ------ ------  ------ ------
                   1,792  2,630  1,754   6,176    255   (232)   (159)  (136)
                  ------ ------ ------ ------- ------ ------  ------ ------
Pretax result     (1,463)(2,261)(1,406) (5,130)  (227)   248     183    204
                  ====== ====== ====== ======= ====== ======  ====== ======

</TABLE>


(2)	Unallocated corporate expenses and Techne's share
of losses by Hemerus Medical, LLC and Nephromics, LLC.
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
